Precision Dermatology

PreCision Dermatology is a spin-out of the dermatology subsidiary of Collegium Pharmaceutical. PreCision develops and markets proprietary formulations of currently approved dermatological products. The primary targeted therapeutic areas are: atopic dermatitis (eczema), acne, rosacea, emollients/anti-aging and steroid responsive dermatoses. PreCision was acquired by Valeant Pharmaceuticals, Inc. (NYSE: VRX) in July 2014 in an all cash transaction for an aggregate purchase price of $500 million.

Related News
Boston Millennia Partners Congratulates PreCision Dermatology Management on $500 Million Sale to Valeant Pharmaceuticals International
With the receipt of Hart-Scott-Rodino clearance, the previously announced acquisition of Precision Dermatology by Valeant Pharmaceuticals International, Inc. for $500 million, closed July 7, 2014. Read Full Release
Boston Millennia Partners Portfolio Company, PreCision Dermatology, Acquires Rights to Clindagel®
Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing prescription products for improving skin health, today announced the acquisition of Clindagel® from Galderma Laboratories. Read Full Release